Trials / Completed
CompletedNCT06143839
VYxeoS Liposomal Italian Observational Study iN the Real Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 113 (actual)
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a prospective, single-arm, non-experimental, observational study in patients in Italy with Acute Myeloid Leukaemia (AML) with myelodysplastic-related changes or therapy related AML initiating treatment with JZP351 (Vyxeos liposomal) in their normal clinical practice.
Conditions
- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Therapy-Related Acute Myeloid Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vyxeos liposomal | Standard of care JZP351 administered intravenously over 90 minutes. |
Timeline
- Start date
- 2023-12-07
- Primary completion
- 2025-10-23
- Completion
- 2025-10-23
- First posted
- 2023-11-22
- Last updated
- 2025-11-20
Locations
24 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06143839. Inclusion in this directory is not an endorsement.